Esperion Therapeutics, Inc. (ESPR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | - | 64,995 | 51,632 | 73,834 |
| Selling, general and administrative | - | 42,996 | 39,975 | 44,185 |
| Research and development | - | 12,557 | 10,397 | 11,461 |
| Cost of goods sold | - | 31,538 | 17,286 | 15,609 |
| Total operating expenses | - | 87,091 | 67,658 | 71,255 |
| Income (loss) from operations | 7,095 | -22,096 | -16,026 | 2,579 |
| Interest expense | 20,486 | 19,431 | 15,082 | 13,723 |
| Loss on extinguishment of debt | - | - | - | -53,235 |
| Other income, net | 666 | 1,072 | 1,584 | 2,454 |
| Net loss | -12,725 | -40,455 | -29,524 | -61,925 |
| Comprehensive loss | -12,725 | -40,455 | -29,524 | -61,925 |
| Net loss per common share - basic (in dollars per share) | -0.06 | -0.21 | -0.15 | -0.33 |
| Net loss per common share - diluted (in dollars per share) | -0.06 | -0.21 | -0.15 | -0.33 |
| Weighted-average shares outstanding - basic (in shares) | 197,546,239 | 196,127,948 | 194,930,830 | 188,793,816 |
| Weighted-average shares outstanding - diluted (in shares) | 197,546,239 | 196,127,948 | 194,930,830 | 188,793,816 |